Clinical Trial ResultsKB-0742 showed a disease control rate of 48% in higher dose cohorts and one partial response in a myxoid liposarcoma patient, indicating on-mechanism clinical activity.
Drug Development ProgressKronos is reallocating resources toward KB-0742, expressing hope for increased efficacy during upcoming updates for dose expansion cohorts.
New Therapy AnnouncementKronos has unveiled KB-9558, a potential new therapy for multiple myeloma, with IND-enabling studies set to complete this year.